Katherine Harris | VP Discovery
teneobio

Katherine Harris, VP Discovery, teneobio

Dr. Katherine Harris has followed her entrepreneurial spirit to work at start-up stage companies where she has thrived in fast-paced work environments, building high-performance teams and processes in the early phases of company formation and growth.  As a leader of pre-clinical research programs, she has taken products from idea to IND filing, managing projects across functional areas and in collaboration with third parties.  Katherine Harris is currently the Vice President of Discovery at Teneobio, a multi-specific biotherapeutic antibody company redirecting the immune system to fight cancer.  She joined Teneobio when the company started lab operations in 2015, playing a key role in both building and managing a high-throughput antibody discovery platform.  Prior to her work at Teneobio, she was a research scientist at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening.  Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Appearances:



Festival of Biologics Day 1 @ 16:30

A bispecific antibody agonist of the IL-2 heterodimeric receptor promotes in vivo expansion of CD8 and NK cells

  • Development and activity of bispecific antibodies that simultaneously bind and activate IL-2Rβγ
  • Bispecific anti-IL-2Rβγ antibodies avoid IL-2Rα and toxicities associated with the trimeric receptor
  • IL-2Rβγ agonist antibodies expand T and NK effector cells both in vitro and in vivo and avoid preferential expansion of Tregs
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers